CancerCOPES Aim 3NCT07852468
Cancer Pain 101: A Digital, Asynchronous Intervention of Pain Management in Advanced Cancer
A study testing Cancer Pain 101 in people with Cancer and Pain, run by University of Alabama at Birmingham at 1 site in United States.
Trial summary
This is a Stage 1 study of a behavioral intervention, which means that a new intervention is being pilot tested to understand whether it is acceptable and feasible for people with advanced cancer to use. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Pain, Advanced Cancer
- What is being tested?
- Cancer Pain 101
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to May 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age ≥ 18 years old
- speaks English
- current, advanced solid tumor cancer diagnosis (stage III or IV)
- endorses cancer-related pain (e.g,. pain, that began, worsened, and/or changed during cancer)
- current opioid prescription OR planning to initiate opioids for cancer pain management
Who cannot join
- observable psychiatric disorders that would interfere with study participation (e.g., dementia, psychosis)
- inability to speak and read English
- inability to provide informed consent
- prior participation in aspects of this study (i.e., K08 Aims 1 and 2)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Alabama at Birmingham
Birmingham, Alabama, 35294
Cyrah Finley, 205-996-2030, cyrahfinley@uabmc.edu
Erin Hornsby, 205-975-2912, eehornsby@uabmc.edu
About this study
This is a Stage 1 study of a behavioral intervention, which means that a new intervention is being pilot tested to understand whether it is acceptable and feasible for people with advanced cancer to use. The purpose of this study is to evaluate whether a series of 3 10-minute videos may help improve prescription opioid pain management and opioid stigma for people living with advanced cancer. Approximately 45 participants will take part in this study at the University of Alabama at Birmingham. People who choose to participate in this study will complete a series of baseline questionnaires, and then will be randomized to one of two groups: 1) the group that gets the video intervention, or 2) the group that gets a written handout with information about cancer pain. About 4 weeks later, all participants will also be asked to fill out another series of questionnaires.
- Conditions
- Cancer, Pain, Advanced Cancer
- Being tested
- Cancer Pain 101
- Keywords
- cancer pain, advanced cancer, digital intervention, pain management
- Medical subject headings
- Neoplasms, Pain, Cancer Pain, Agnosia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cancer Pain 101Behavioural
The study intervention is Cancer Pain 101. Cancer Pain 101 is a 3-part educational video series, designed to be delivered asynchronously. Each video is approximately 10 minutes long and is narrated by a multidisciplinary team, including a psychologist, oncologist, palliative care clinician, and pharmacist.
| Study group | Role | What they receive |
|---|---|---|
| Cancer Pain 101 Intervention | Experimental | Participants randomized to the intervention group will have access to three 10-minute videos through a digital application. The videos cover cancer pain, pain medications, and pain self-management skills, and will be available for four weeks. Receives: Behavioral: Cancer Pain 101 |
| Educational Control | No intervention | Participants in the educational control condition will receive a written handout about cancer pain, which is widely available and published by the American Cancer Society; they will not have access to the intervention videos. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants who watch at least one video
Count participants who watch at least one video
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionApr 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University of Alabama at BirminghamThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Hailey Bulls, University of Alabama at Birmingham
- Investigators
- Hailey W Bulls, PhD, Principal investigator, University of Alabama at Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07852468
- Sponsor's protocol ID
- STUDY00000160
- Other IDs
- K08CA263317
- Acronym
- COPES Aim 3
- Status last verified
- Oct 2026
- First submitted
- 23 Sep 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The proposed research will include data from a total of 120 patients (75 Aims 1 and 2; 45 Aim 3) with advanced cancer. The final dataset will include self-reported demographic data and survey data from pilot trial assessments. All data in our analysis will be deidentified. No identifying information will be retained past the conclusion of the K08 study period. The data collected will be used for publication purposes and will be made available for public use upon completion of our study and the initial dissemination of our research results. Any data shared will be de-identified.
Publications
Bulls HW, Hamm M, Wasilko R, de Abril Cameron F, Belin S, Goodin BR, Liebschutz JM, Wozniak A, Sabik LM, Merlin JS, Schenker Y. Manifestations of Opioid Stigma in Patients With Advanced Cancer: Perspectives From Patients and Their Support Providers. JCO Oncol Pract. 2022 Oct;18(10):e1594-e1602. doi: 10.1200/OP.22.00251. Epub 2022 Jul 25.
PubMed 35878073Bulls HW, Chu E, Goodin BR, Liebschutz JM, Wozniak A, Schenker Y, Merlin JS. Framework for opioid stigma in cancer pain. Pain. 2022 Feb 1;163(2):e182-e189. doi: 10.1097/j.pain.0000000000002343.
PubMed 34010940